Polyethylenimine Hybrid Thin-Shell Hollow Mesoporous Silica Nanoparticles as Vaccine Self-Adjuvants for Cancer Immunotherapy

• Published in: ACS applied materials & interfaces Vol. 11; no. 51; pp. 47798 - 47809
• Main Authors: Liu, Qianqian, Zhou, Yajie, Li, Mo, Zhao, Liang, Ren, Jingli, Li, Danqi, Tan, Zhengping, Wang, Ke, Li, Heli, Hussain, Mubashir, Zhang, Lianbin, Shen, Guanxin, Zhu, Jintao, Tao, Juan
• Format: Journal Article
• Language: English
• Published: United States American Chemical Society 26.12.2019
• Subjects: Adjuvants, Immunologic - chemistry; Animals; Cancer Vaccines - chemistry; Dendritic Cells - metabolism; Humans; Immunotherapy - methods; Nanoparticles - chemistry; Polyethyleneimine - chemistry; Silicon Dioxide - chemistry; anticancer immunity; polyethyleneimine; adjuvant; cancer vaccine; hollow mesoporous silica nanoparticles
• ISSN: 1944-8244; 1944-8252
• DOI: 10.1021/acsami.9b19446

Conventional adjuvants (e.g., aluminum) are insufficient to trigger cell-mediated immunity, which plays a crucial role in triggering specific immunity against cancer. Therefore, developing appropriate adjuvants for cancer vaccines is a central way to stimulate the antitumor immune response. Hollow mesoporous silica nanoparticles (HMSNs) have been proven to stimulate Th1 antitumor immunity in vivo and promote immunological memory in the formulation of novel cancer vaccines. Yet, immune response rates of existing HMSNs for anticancer immunity still remain low. Here, we demonstrate the generation of polyethylenimine (PEI)-incorporated thin-shell HMSNs (THMSNs) through a facile PEI etching strategy for cancer immunotherapy. Interestingly, incorporation of PEI and thin-shell hollow structures of THMSNs not only improved the antigen-loading efficacy and sustained drug release profiles but also enhanced the phagocytosis efficiency by dendritic cells (DCs), enabled DC maturation and Th1 immunity, and sustained immunological memory, resulting in the enhancement of the adjuvant effect of THMSNs. Moreover, THMSNs vaccines without significant side effects can significantly reduce the potentiality of tumor growth and metastasis in tumor challenge and rechallenge models, respectively. THMSNs are considered to be promising vehicles and excellent adjuvants for the formulation of cancer vaccines for immunotherapy.